Group 1 - The core viewpoint of the news highlights the performance and valuation of Aiwei Technology, which closed at 25.1 yuan, up 3.63%, with a rolling PE ratio of 70.85, marking a new low in 804 days, and a total market value of 1.707 billion yuan [1] - The average PE ratio for the medical device industry is 55.28, with a median of 38.06, placing Aiwei Technology at the 93rd position in the industry ranking [1] - As of the first quarter of 2025, there are 2 institutions holding shares in Aiwei Technology, with a total of 10.42 thousand shares valued at 0.02 million yuan [1] Group 2 - Aiwei Technology specializes in the research, development, production, sales, and service of medical clinical testing analysis instruments and related in vitro diagnostic reagents and medical consumables [1] - The company holds a total of 259 authorized patents (including 97 domestic invention patents and 18 overseas authorized patents) and has 30 software copyrights, along with various medical device registration certificates [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, a year-on-year increase of 24.63%, with a gross profit margin of 55.59% [1]